Shuttle Pharmaceuticals
SHPH
4 hedge funds and large institutions have $26.8K invested in Shuttle Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
31% less capital invested
Capital invested by funds: $38.8K → $26.8K (-$12K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$842 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$5.05K |
| 2 |
VF
Virtu Financial
New York
|
-$4.21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $15K | – | – | – |
|
|
2
Renaissance Technologies
New York
| $7K | -$5.05K | -6 | -43% |
|
|
VF
3
Virtu Financial
New York
| $4K | -$4.21K | -5 | -50% |
|
|
4
UBS Group
Zurich,
Switzerland
| $455 | +$842 | +1 | New |
|
|
FDCDDQ
5
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $203 | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $102 | – | – | – |
|
7
Wells Fargo
San Francisco,
California
| $22 | – | – | – |
|
SHPH Hedge Fund Activity: Q1 2024 in Review
4 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Shuttle Pharmaceuticals (SHPH) for Q1 2024, worth a combined $26.8K — down 31% from $38.8K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SHPH positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $842. The largest seller was Renaissance Technologies, cutting an estimated $5.05K.
- 4 institutional investors held Shuttle Pharmaceuticals (SHPH) as of Q1 2024, up from 3 in Q4 2023.
- Funds reported $26.8K of Shuttle Pharmaceuticals stock for Q1 2024, down 31% quarter-over-quarter.
- 1 fund opened new Shuttle Pharmaceuticals positions in Q1 2024 and 0 closed out, a net change of +1 holder.
- The largest Shuttle Pharmaceuticals buyer in Q1 2024 was UBS Group, an estimated $842 added.
- The largest Shuttle Pharmaceuticals seller in Q1 2024 was Renaissance Technologies, an estimated $5.05K sold.
Based on aggregated 13F filings for Q1 2024.